6990:HKEXSichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H Analysis

The stock is trading at HK$474.2, comfortably above the 20‑day SMA of HK$453.7 and the 50‑day SMA of HK$456.1, indicating short‑term price strength. Momentum indicators are mixed: the RSI sits at 57, suggesting neutral momentum, while the MACD line has turned bullish with a positive histogram, supporting a modest upside bias. Volume is on an increasing trend, adding confidence to the recent price gains. However, volatility is extremely high at over 41% on a 30‑day basis, and the beta of 0.32 shows the stock moves less than the market, underscoring a risk‑adjusted profile that is still volatile. Fundamental metrics reveal a forward PE of 142.7 and a price‑to‑book of 19.7, far above the industry PE average of 27.3, highlighting significant overvaluation. The company is loss‑making with negative operating and free cash flow, and a negative ROE, which further tempers enthusiasm.
On the upside, Kelun‑Biotech boasts a deep oncology and immunology pipeline, multiple ADC candidates, and strategic collaborations with global partners such as Merck Sharp & Dohme and Harbour BioMed, which could unlock future revenue streams. The “Extreme Greed” sentiment on the fear‑greed index reflects strong market appetite despite the weak earnings backdrop. Given the high valuation, elevated volatility, and regulatory complexities inherent to biotech, investors should weigh growth potential against the current financial weakness. The stock’s liquidity appears adequate, with volume surpassing its 10‑day average, but the lack of dividend and the sizable max drawdown of nearly 40% remain cautionary signals.